#United States #Baltimore #Cancer Diagnostics #DELFI Diagnostics #Amoolya Singh

DELFI Diagnostics Welcomes Dr. Amoolya Singh as Chief Technology Officer

In an exciting strategic move to enhance its technology leadership, DELFI Diagnostics, Inc. has announced the appointment of Dr. Amoolya Singh as its new Chief Technology Officer (CTO). This action signifies the company’s commitment to pioneering advanced solutions in cancer detection, particularly through blood-based liquid biopsy tests.

Dr. Singh's primary role will involve steering DELFI Diagnostics' innovative technology roadmap, focusing on its state-of-the-art AI-driven fragmentomics platform. This transformative technology is designed to provide unparalleled genomic insights, enabling more effective early cancer detection at an unprecedented price point. That's a game-changer for individuals and families affected by cancer, providing access to testing that was previously out of reach.

CEO Susan Tousi expressed her enthusiasm for Dr. Singh’s appointment, highlighting her impressive track record in developing breakthrough genomic technologies. "Dr. Singh's expertise in computational biology makes her the perfect candidate to propel our mission forward," said Tousi. Her experience in constructing and scaling complex diagnostic platforms will be instrumental as DELFI enters a new growth phase.

Dr. Singh comes to DELFI Diagnostics with over 20 years of rich experience connecting biotechnology with computational science. Before joining DELFI, she held senior positions at Grail, where she was responsible for leading data science efforts, and at Calico, Alphabet’s subsidiary for drug discovery.

In her vision for the future, Dr. Singh noted, "Reliable, affordable, and non-invasive cancer detection is among the most promising frontiers in healthcare, with the potential to change how we diagnose and treat cancer." Her passion for scientific excellence aligns perfectly with DELFI’s mission to revolutionize cancer detection, making this relationship particularly meaningful.

Dr. Singh earned a Ph.D. in Computational Biology along with a Master’s in Computer Science from the University of California at Berkeley. She also holds a Bachelor of Science degree in Biology and Computer Science from Carnegie Mellon University. Further enhancing her scientific credentials, Dr. Singh completed postdoctoral fellowships at the European Molecular Biology Laboratory in Heidelberg, Germany, and at Emory University.

About DELFI Diagnostics

DELFI Diagnostics is focused on creating next-generation blood tests that offer accessible and precise cancer detection. Their cutting-edge tests aim to address significant public health issues, especially in underserved demographics, potentially saving lives worldwide. The company’s initial laboratory-developed screening test, FirstLook Lung, can detect lung cancer in patients eligible for lung cancer screening through a simple blood draw that integrates with routine medical procedures.

Utilizing the principles of fragmentomics, DELFI's tests capture the chaotic nature of cancer cells and the unique patterns they leave behind in cell-free DNA (cfDNA) fragments, which can be detected in the bloodstream. By leveraging advanced machine learning applied to whole-genome sequencing data, the technology identifies cfDNA patterns that correlate with cancer presence. FirstLook Lung uses millions of data points to reliably detect early-stage lung cancer with an impressive negative predictive value of 99.8%. Though this test is not yet FDA-approved, it represents a significant leap toward effective cancer detection methods in clinical settings.

For more information about DELFI Diagnostics and their innovative testing technologies, you can visit their websites at www.delfidiagnostics.com and www.firstlooktest.com.